Fig. 4

Analysis of hOA-DN30 tumor inhibition in vivo. a Analysis of tumor growth in NOD-SCID mice subcutaneously injected with GTL-16 MET-addicted gastric carcinoma cells treated with increasing concentrations (3.3, 10, 60 mg/kg) of hOA-DN30 3xweek. b Analysis of MET phosphorylation in tumors collected at the end of the experiment shown in panel a. Left, representative images; right, quantification of the staining represented as the percentage with respect to untreated tumors. Bars represent SEM. c Quantification of circulating human MET-ECDs in tumor-bearing NOD-SCID mice treated with hOA-DN30 (30 mg/kg). d Analysis of tumor growth in NOD-SCID mice subcutaneously injected with EBC-1 MET-addicted lung carcinoma cells treated with increasing concentrations (5, 10, 30 mg/kg) of hOA-DN30 1xweek. e Analysis of tumor growth in NOD-SCID mice subcutaneously injected with EBC-1 MET-addicted lung carcinoma cells treated with the same total amount of hOA-DN30 administered with different schedules (60 mg/kg 1x2weeks or 10 mg/kg 3xweek). f Analysis of tumor growth in NOD-SCID mice subcutaneously injected with SNU-5 MET-addicted gastric cancer cells treated with 30 mg/kg of hOA-DN30 2xweek. Red boxes: period of hOA-DN30 administration; arrows: antibody deliveries; bars represent SD. Statistical significance evaluated by One-way Anova analysis (panel b) or Two-way Anova analysis (panels a, c-f) is reported; ****, p <0.0001; ***, p<0.001; **, p<0.01; *, p<0.05